spironolactone has been researched along with Bladder Cancer in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone was identified as a potent NER inhibitor." | 5.72 | A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. ( Attwood, K; Cao, Q; Chatta, G; Goodrich, DW; Guru, KA; Katsuta, E; Li, QJ; Smith, GJ; Takabe, K; Wang, J; Wang, L; Wei, L; Wu, Y; Xu, B; Xu, D, 2022) |
| "Spironolactone was identified as a potent NER inhibitor." | 1.72 | A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. ( Attwood, K; Cao, Q; Chatta, G; Goodrich, DW; Guru, KA; Katsuta, E; Li, QJ; Smith, GJ; Takabe, K; Wang, J; Wang, L; Wei, L; Wu, Y; Xu, B; Xu, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, D | 1 |
| Cao, Q | 1 |
| Wang, L | 1 |
| Wang, J | 1 |
| Xu, B | 1 |
| Attwood, K | 1 |
| Wei, L | 1 |
| Wu, Y | 1 |
| Smith, GJ | 1 |
| Katsuta, E | 1 |
| Takabe, K | 1 |
| Chatta, G | 1 |
| Guru, KA | 1 |
| Goodrich, DW | 1 |
| Li, QJ | 1 |
| Chuang, YW | 1 |
| Yu, MC | 1 |
| Huang, ST | 1 |
| Yang, CK | 1 |
| Chen, CH | 1 |
| Lo, YC | 1 |
| Lin, CL | 1 |
| Shu, KH | 1 |
| Yu, TM | 1 |
| Kao, CH | 1 |
2 other studies available for spironolactone and Bladder Cancer
| Article | Year |
|---|---|
A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; | 2022 |
Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2017 |